EMA — authorised 17 August 2022
- Marketing authorisation holder: ONCOPEPTIDES AB
- Status: approved
🇪🇺 Pepaxto in European Union
EMA authorised Pepaxto on 17 August 2022
Marketing authorisation
Pepaxto in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in European Union
Frequently asked questions
Is Pepaxto approved in European Union?
Yes. EMA authorised it on 17 August 2022.
Who is the marketing authorisation holder for Pepaxto in European Union?
ONCOPEPTIDES AB holds the EU marketing authorisation.